| Human papillomavirus-related oropharyngeal cancer M Taberna, M Mena, MA Pavón, L Alemany, ML Gillison, R Mesía Annals of Oncology 28 (10), 2386-2398, 2017 | 413 | 2017 |
| The multidisciplinary team (MDT) approach and quality of care M Taberna, F Gil Moncayo, E Jané-Salas, M Antonio, L Arribas, ... Frontiers in oncology 10, 85, 2020 | 231 | 2020 |
| Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma M Oliva, A Spreafico, M Taberna, L Alemany, B Coburn, R Mesia, LL Siu Annals of oncology 30 (1), 57-67, 2019 | 207 | 2019 |
| Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... The Lancet Oncology 22 (4), 463-475, 2021 | 127 | 2021 |
| Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma M Taberna, M Oliva, R Mesía Frontiers in oncology 9, 383, 2019 | 102 | 2019 |
| Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis H Mehanna, M Taberna, C Von Buchwald, S Tous, J Brooks, M Mena, ... The Lancet Oncology 24 (3), 239-251, 2023 | 78 | 2023 |
| Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients M Mena, M Taberna, S Tous, S Marquez, O Clavero, B Quiros, B Lloveras, ... Oral Oncology 78, 137-144, 2018 | 71 | 2018 |
| Nutritional changes in patients with locally advanced head and neck cancer during treatment L Arribas, L Hurtós, M Taberna, I Peiró, E Vilajosana, A Lozano, ... Oral Oncology 71, 67-74, 2017 | 71 | 2017 |
| SEOM clinical guidelines for the treatment of head and neck cancer (2020) R Mesia, L Iglesias, J Lambea, J Martínez-Trufero, A Soria, M Taberna, ... Clinical and Translational Oncology 23, 913-921, 2021 | 64 | 2021 |
| Significant changes in sexual behavior after a diagnosis of human papillomavirus‐positive and human papillomavirus‐negative oral cancer M Taberna, RC Inglehart, RKL Pickard, C Fakhry, A Agrawal, ML Katz, ... Cancer 123 (7), 1156-1165, 2017 | 59 | 2017 |
| The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma M Martel, L Alemany, M Taberna, M Mena, S Tous, S Bagué, ... Oral oncology 64, 37-43, 2017 | 47 | 2017 |
| Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651 RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, ... Journal of Clinical Oncology 41 (12), 2166-2180, 2023 | 46 | 2023 |
| Late toxicity after radical treatment for locally advanced head and neck cancer M Taberna, AJ Rullan, C Hierro, V Navarro, S Vázquez, A Lozano, ... Oral oncology 51 (8), 795-799, 2015 | 46 | 2015 |
| Assessing the performance of clinical natural language processing systems: development of an evaluation methodology L Canales, S Menke, S Marchesseau, A D’Agostino, C del Rio-Bermudez, ... JMIR Medical Informatics 9 (7), e20492, 2021 | 41 | 2021 |
| Might oral human papillomavirus (HPV) infection in healthy individuals explain differences in HPV-attributable fractions in oropharyngeal cancer? A systematic review and meta … M Mena, M Taberna, L Monfil, M Arbyn, S de Sanjosé, FX Bosch, ... The Journal of infectious diseases 219 (10), 1574-1585, 2019 | 37 | 2019 |
| Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe M Mena, J Frias-Gomez, M Taberna, B Quirós, S Marquez, O Clavero, ... Scientific reports 10 (1), 13219, 2020 | 35 | 2020 |
| HPV knowledge gaps and information seeking by oral cancer patients RC Inglehart, M Taberna, RKL Pickard, M Hoff, C Fakhry, E Ozer, M Katz, ... Oral Oncology 63, 23-29, 2016 | 35 | 2016 |
| Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location R Seijas-Tamayo, J Fernández-Mateos, JC Adansa Klain, R Mesía, ... Clinical and Translational Oncology 18, 1114-1122, 2016 | 32 | 2016 |
| A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with … R Mesía, S Vázquez, JJ Grau, JA García-Sáenz, A Lozano, C García, ... International Journal of Radiation Oncology* Biology* Physics 94 (2), 289-296, 2016 | 32 | 2016 |
| Role of human papillomavirus infection in head and neck cancer in Italy: the HPV-AHEAD study M Tagliabue, M Mena, F Maffini, T Gheit, B Quirós Blasco, D Holzinger, ... Cancers 12 (12), 3567, 2020 | 31 | 2020 |
